A pilot study of weekly brentuximab vedotin in patients with CD30+ malignancies resistant to brentuximab vedotin every 3 weeks.

ABSTRACT:

SUBMITTER: Poston JN 

PROVIDER: S-EPMC6589112 | biostudies-literature | 2019 Jul

REPOSITORIES: biostudies-literature